Edition:
United States

People: Palatin Technologies Inc (PTN)

PTN on American Stock Exchange

0.57USD
2 Dec 2016
Change (% chg)

$0.01 (+2.57%)
Prev Close
$0.56
Open
$0.59
Day's High
$0.59
Day's Low
$0.56
Volume
1,909,528
Avg. Vol
2,241,525
52-wk High
$0.90
52-wk Low
$0.36

Spana, Carl 

Dr. Carl Spana, Ph.D., is President, Chief Executive Officer, Director of the Company. He has been a director of Palatin since June 1996 and has been a director of our wholly-owned subsidiary, RhoMed Incorporated, since July 1995. From June 1996 through June 14, 2000, Dr. Spana served as an executive vice president and our chief technical officer. From June 1993 to June 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and The Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From July 1991 to June 1993, Dr. Spana was a Research Associate at Bristol-Myers Squibb, a publicly traded pharmaceutical company, where he was involved in scientific research in the field of immunology. He was previously a member of the board of the life science company AVAX Technologies, Inc. Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University.

Basic Compensation

Total Annual Compensation, USD 657,500
Restricted Stock Awards, USD 226,800
Long-Term Incentive Plans, USD --
All Other, USD 253,769
Fiscal Year Total, USD 1,138,070

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --